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incidence and epidemiology
Follicular lymphomas (FLs) are the second most frequent subtype
of nodal lymphoid malignancies in Western Europe. The annual
incidence of this disease has rapidly increased during recent
decades and has risen from 2–3/100 000 during the 1950s to 5–7/
100 000 recently.
diagnosis and pathology/molecular
biology
Diagnosis should be based on a surgical specimen/excisional
lymph node biopsy. Core biopsies should only be carried out in
patients without easily accessible lymph nodes (e.g. retroperi-
toneal bulk), keeping in mind the possible heterogeneity of FL
grading difficult to appreciate on core biopsies. Re-biopsy may
be required if material is not appropriate. Fine-needle aspira-
tions are inappropriate for a reliable diagnosis.
The histological report should give the diagnosis according to
the World Health Organization (WHO) classification. Grading
of lymph node biopsies is carried out according to the number
of blasts/high power field (Table 1). FL grade 3B (with sheets of
blasts) is considered an aggressive lymphoma and treated ac-
cordingly [1], whereas grades 1, 2, and 3A should be treated as
indolent disease [2]. Review, especially of grade 3A or 3B, by an
expert haematopathologist is advised if the infiltration pattern is
unusual (diffuse areas, even with small cells).
Extended ribonucleic acid profiling suggests a more favourable
clinical course in cases with infiltrating T cells, in comparison to
cases with unspecific macrophage bystander cells [3]; however,
this technique is not yet applicable in clinical routine practice. In
addition, several recent immunohistochemistry studies have
reported conflicting data; hence, biological parameters are still in-
vestigational for prognostic assessment and are not yet suitable
for clinical decision-making [4, 5]. However, if possible, addition-
al biopsy material should be stored fresh frozen to allow addition-
al molecular (currently still investigational) analyses.
staging and risk assessment
Since treatment substantially depends on the stage of the disease,
initial staging should be thorough, particularly in the small pro-
portion of patients with early stages I and II (10%–15%) (Table 2).
Initial work-up should include a computed tomography (CT)
scan of the neck, thorax, abdomen and pelvis, and a bone marrow
aspirate and biopsy (Table 3). Positron emission tomography–
computed tomography (PET-CT) scan is not mandatory but may
contribute to identify areas with high standardised uptake values
suspected of disease transformation [6], and may be used as base-
line for response assessment (see below). In rare stage I/II cases,
PET-CT scan may be also useful to confirm localised stage I/II
disease before localised radiotherapy [IV, C].
A complete blood count, routine blood chemistry including
lactate dehydrogenase, β2-microglobulin and uric acid as well as
screening tests for human immunodeficiency virus (HIV) and
hepatitis B and C are required. The staging is carried out according
to the Ann Arbor classification system (Table 2), with mention of
bulky disease >5 cm when appropriate.
For prognostic purposes, a ‘Follicular Lymphoma-specific
International Prognostic Index’ (FLIPI, Table 4) has been estab-
lished [I, A] [7, 8]. A revised FLIPI 2 (incorporating β2-microglo-
bulin, diameter of largest lymph node, bone marrow involvement
and haemoglobin level) has been recently suggested for patients
requiring treatment [9].
treatment
first line
stage I–II. In the small proportion of patients with limited
non-bulky stages I–II, radiotherapy (involved field, 24–36 Gy) is
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the preferred treatment having a curative potential, whereas the
2 × 2 Gy schedule is inferior and is merely palliative [II, B] [10].
In selected cases, watchful waiting or rituximab monotherapy
may be considered to avoid the side-effects of radiation (e.g.
cervical: sicca syndrome; abdominal: myeloablative suppression)
[11, 12].
In stage I–II patients with large tumour burden or adverse
prognostic features, systemic therapy as indicated for advanced
stages should be applied; a radiation consolidation may be con-
sidered depending on tumour location and expected side-effects
[IV, B] [12].
stages III–IV
induction: In the majority of patients with advanced stage III
and IV disease, no curative therapy is yet established. Since the
natural course of the disease is characterised by spontaneous
regressions in 10%–20% of cases and varies significantly from case
to case, therapy should be initiated only upon the occurrence of
symptoms including B symptoms, haematopoietic impairment,
bulky disease, vital organ compression, ascites, pleural effusion, or
rapid lymphoma progression [I, A]. In four randomised trials, an
early initiation of therapy in asymptomatic patients did not result
in any improvement of disease-specific survival or overall survival
(OS) [13]. In a recent study, early initiation of rituximab resulted
in improved progression-free survival (PFS) (80% versus 48%,
P < 0.001), but the benefit on long-term outcome has to be
determined [14], and the benefit of rituximab maintenance in this
setting appears doubtful [15]. Thus, the current therapeutic
approach is based on clinical risk factors, symptoms and patient
perspective (Figure 1).
If complete remission and long PFS is to be achieved, rituxi-
mab in combination with chemotherapy such as CHOP (cyclo-
phosphamide, doxorubicin, vincristine and prednisone) or
bendamustine should be used [I, B] [17, 18]. CVP (cyclophos-
phamide, vincristine and prednisone) combination results in
inferior PFS, but no impact on OS was observed between these
chemotherapy regimens [19]. Full courses of purine analogue-
based schemes [FC (fludarabine and cyclophosphamide) or FM
(fludarabine and mitoxantrone)] are not recommended due to
higher haematological toxicities [19]. In case of (histological or
clinical) characteristics of transformation to aggressive lymph-
oma, an anthracycline-based regimen should be preferred.
Four prospective first-line trials, two salvage trials and a sys-
tematic meta-analysis confirmed an improved overall response,
PFS and OS if rituximab was added to chemotherapy (Table 5)
[20–23, 25].
A brief course of chemoimmunotherapy with full rituximab
course is an alternative in elderly patients, with good efficacy
and low toxicity [II, B] [24].
Antibody monotherapy (rituximab, radioimmunotherapy) or
chlorambucil plus rituximab remains an alternative in patients
with a low-risk profile or contraindications for a more intensive
chemoimmunotherapy [III, B] [26, 27].
Table 2. Ann Arbor classification
Stage Area of involvement
I (IE) One lymph node region or extralymphatic site (IE)
II (IIE) Two or more lymph node regions or at least one
lymph node region plus a single localised
extralymphatic site(IIE) on the same side of the
diaphragm
III (IIIE, IIIS) Lymph node regions or lymphoid structures (e.g.
thymus, Waldeyer’s ring) on both sides of the
diaphragm with optional localised extranodal site
(IIIE) or spleen (IIIS)
IV Diffuse or disseminated extralymphatic organ
involvement
For all stages
A no symptoms
B unexplained fever of >38°C, drenching night sweats;
or loss of >10% body weight within 6 months
Table 3. Diagnostic work-up
History B symptoms
Physical
examination
Peripheral lymph nodes, liver, spleen
Laboratory
work-up
Blood and differential count
Optional: FACS, PCR for BCL-2 rearrangement
LDH (suspected transformation), uric acid
electrophoresis (optional: immune fixation)
β2-microglobulin (FLIPI 2)
Serology Hepatitis B, C and HIV serology
Imaging Chest X-ray
Abdominal ultrasound
CT neck, chest, abdomen, pelvis
MRT only in selected locations (CNS)
Optional: PET
Bone marrow Histology
Cytology
Optional: FACS, PCR for BCL-2 rearrangement
Toxicity Electrocardiogram, cardiac ultrasound (before
anthracyclines, ASCT)
Creatinine clearance
Optional: reproductive counselling in young
patients
FACS, fluorescence-activated cell sorting; PCR, polymerase chain
reaction; LDH, lactate dehydrogenase; FLIPI 2, Follicular Lymphoma
International Prognostic Index 2; HIV, human immunodeficiency
virus; MRT, magnetic resonance tomography; CNS, central nervous
system; PET, positron emission tomography; ASCT, autologous
stem-cell transplantation; BCL-2, B-cell lymphoma 2.
Table 1. Grading of follicular lymphoma
Grade Description
1 ≤5 blasts/high power field
2 6–15 blasts/high power field
3A >15 blasts/high power field, centroblasts with intermingled
centrocytes
3B >15 blasts/high power field, pure sheets of blasts
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In patients with positive hepatitis B serology, prophylactic
antiviral medication is strongly recommended [I, A] [28].
consolidation/maintenance
Rituximab maintenance for 2 years improves PFS (75% versus
58% after 3 years, P < 0.0001) [I, B] [29], whereas a shorter main-
tenance period results in inferior benefit [29, 30].
Radioimmunotherapy consolidation prolongs PFS after chemo-
therapy only, but its benefit seems to be inferior in comparison to
rituximab maintenance for 2 years [II, B] [31, 32].
Myeloablative consolidation followed by autologous stem-cell
transplantation (ASCT) prolongs PFS after chemotherapy only,
but its benefit after a rituximab-containing induction is minor and
no OS has been observed [33]. Therefore, such an approach is not
recommended in first-line therapy of responding patients [I, D].
relapsed disease
A repeated biopsy is strongly recommended with consideration
of a PET-guided biopsy to rule out a secondary transformation
into aggressive lymphoma.
As at first presentation, observation is an accepted approach
in asymptomatic patients with low tumour burden.
Selection of salvage treatment depends on efficacy of prior
regimens. In early relapses (<12–24 months), a non-cross-resist-
ant scheme should be preferred (e.g. bendamustine after CHOP
or vice versa). Rituximab should be added if the previous
Table 4. ‘Follicular Lymphoma-specific International Prognostic Index’ (FLIPI) risk factors
Parameter Definition of risk factors
FLIPI 1 FLIPI 2
Nodal sites >4 lymph node regions (definition in [7]) Long diameter of largest lymph node >6 cm
Age Above 60 years Above 60 years
Serum marker Elevated LDH Elevated β2-microglobulin
Stage Advanced (III–IV according to Ann Arbor classification) Bone marrow involvement
Haemoglobin <12 g/dl <12 g/dl
With 0–1 risk factors, low risk; 2, intermediate risk; 3–5, high risk.
LDH, lactate dehydrogenase.
Prognosis
stage
FLIPI 1/2
grade
Asymptomatic cases:
Watch and wait Mild symptoms:
Non-chemotherapy treatment
Ritumixab
Radioimmunotherapy
High tumour burden:
Immuno-chemotherapy
R-CHOP
R-CVP
R-bendamustine
+/– Rituximab maintenance
(or radioimmunotherapy)
Symptoms
Not mild 
Life/organ threatening
Evaluate
Choose among
Patient priority
Longer survival
Long remission
Better quality of life
Figure 1. Therapeutic algorithm. Modified from [16]. Reproduced with permission of Informa Healthcare, copyright ©2009, Informa Healthcare.
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antibody-containing scheme achieved >6 months duration of re-
mission [IV, B].
In symptomatic cases with low tumour burden, a rituximab
monotherapy may be applied.
Radioimmunotherapy (90yttrium-ibritumomab-tiuxetan) repre-
sents an effective therapeutic approach, especially in elderly patients
with comorbidities not appropriate for chemotherapy. Otherwise,
it should be applied preferably as consolidation [IV, B].
Rituximab maintenance for up to 2 years has a favourable side-
effect profile and, based on a systematic meta-analysis, substantial-
ly prolongs PFS and OS in relapsed disease even after antibody-
containing induction in patients who have not received antibody
as first-line therapy [I, A] [34]. A second-line maintenance treat-
ment has not been investigated in the setting of maintenance use
in first-line and probably should not be used for those patients
who had relapsed during their first maintenance period [IV, D].
High-dose chemotherapy with ASCT prolongs PFS and OS and
should be considered, especially in patients with short-lived first
remissions after rituximab-containing regimens, but its role has to
be redefined in the rituximab era [I, B] [4, 35, 36]. A subsequent
rituximab maintenance may achieve some benefit [II, B] [37].
In selected younger patients with high-risk profile or relapse
after ASCT, a potentially curative allogeneic stem-cell transplant-
ation (preferably with dose-reduced conditioning) may be discussed
in relapsed disease, especially in early relapses and refractory
disease [IV, B] [4].
response evaluation
Adequate radiological tests should be carried out midterm and
after completion of chemotherapy. Patients with insufficient or
lacking response [less than partial response (PR)] should be
evaluated for early salvage regimens. PR patients may convert to
complete response after post-induction treatment.
No consensus could be reached on the routine application of
PET-CT for response evaluation. PET-CT identifies a small group
(20%–25%) of patients with a poorer prognosis [38, 39]; however,
optimal interventional approaches for this group of patients
remain undefined.
Table 5. Combined chemoimmunotherapy in follicular lymphoma (first line)
Study Total no.
of patients
Median follow-up
(months)
Overall response Time-to-treatment failure
(months)
Overall survival
Marcus et al. [20] R-CVP 321 53 81% (P < 0.0001) 27 (P < 0.0001) 83% (4 years)
(P = 0.029)
Hiddemann et al. [21] R-CHOP 428 58 96% NR (P < 0.001) 90% (2 years)
(P = 0.0493)
Herold et al. [22] R-MCP 201 48 92% (P = 0.0009) NR (P < 0.0001) 87% (P = 0.0096)
Bachy et al. [23] R-CHVP-IFN 358 99 81% (P = 0.035) 66 (P = 0.0004) 79% (8 years)
(P = 0.076)
Rummel et al. [17] BR 139 34 93% NR 84% (4 years)
Vitolo et al. [24] 4x R-FND + 4x
R ± R maintenance
234 42 86% NR 89% (3 years)
P: Significance levels in comparison to chemotherapy only.
R-CVP, cyclophosphamide, vincristine and prednisolone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; R-MCP,
methotrexate, procarbazine and lomustine; R-CHVP-IFN, rituximab, cyclophosphamide, doxorubicin, etoposide, prednisone, interferon; BR,
bendamustine–rituximab; R-FND, cyclophosphamide, vincristine and prednisolone; NR, no response.
Table 6. Recommended follow-up after end of therapy
Examination Details Year 1–2 Year 3–5 Year >5
History B symptoms Every 3 months Twice annually Annually
Physical
examination
Particular: peripheral lymph nodes, liver,
spleen
Every 3 months Twice annually Annually
Laboratory work-up Blood and differential count Every 3 months Twice annually Annually
LDH Every 3 months Twice annually Annually
Imaging Abdominal ultrasound Twice annually Every 12 months If progress
suspected
CT neck, chest, abdomen, pelvis Optional: twice
annually
Optional: every 12
months
If progress
suspected
LDH, lactate dehydrogenase; CT, computed tomography.
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Minimal residual disease (MRD) analysis by polymerase
chain reaction at the end of the treatment is an independent pre-
dictor of long-term outcome, but should not guide therapeutic
strategies outside clinical studies.
personalisedmedicine
As various therapeutic approaches may achieve durable responses
in the vast majority of patients, the selection of optimal treatment
is mainly based on clinical risk factors, symptoms and patient
perspective (Figure 1). PET- and MRD-based tailored treatments
are currently evaluated in studies but are not yet routine clinical
practice.
Paediatric FL is an FL variant originally described in children,
but occurs in adults as well. It is characterised by a localised disease,
the absence of B-cell lymphoma 2 aberrations, lack of t(14;18),
grade 3 and a high proliferation rate. It shows a much more indo-
lent course and should be managed with less intensity, e.g. local
therapy only, despite histologically more aggressive features [40].
New agents (including PI3 kinase inhibitors and Bruton’s
tyrosine kinase inhibitors) are currently being investigated [41].
Idelalisib has been approved by the United States Food and
Drug Administration, and has been recommended for approval
by European Medicines Agency for use for adult patients with
follicular lymphoma that has not responded to two previous
lines of treatments.
follow-up and long-term implications
The following recommendations are based on consensus rather
than on evidence (see Table 6):
• History and physical examination every 3 months for 2 years,
every 4–6 months for 3 additional years, and subsequently
once a year with special attention to transformation and sec-
ondary malignancies including secondary leukaemia [V, C].
• Blood count and routine chemistry every 6 months for 2 years,
then only as needed for evaluation of suspicious symptoms.
• Evaluation of thyroid function in patients with irradiation of
the neck at 1, 2 and 5 years.
Table 7. Consensus-driven recommendations outside clinical studies
Low tumour burden High tumour burden
Stage I/II Stage III/IV Stage III/IV (<65 yearsa) Stage III/IV (>65 yearsa)
Front line
Radiotherapy (involved
field)
24–36 Gy
In selected cases,
watchful waiting
Watch and wait
In symptomatic cases, consider
rituximab monotherapy
Chemoimmunotherapy
(e.g. R-CHOP, R-CVP, BR)
In selected cases, rituximab
monotherapy
Chemoimmunotherapy
(e.g. R-CVP, BR, R-CHOP) or
brief chemoimmunotherapy
In selected cases,
rituximab–chlorambucil
rituximab monotherapy
– – CR/PR
Rituximab maintenance
(every 2 months, up to 2 years)
CR/PR
Rituximab maintenance
(every 2 months, up to 2 years)
Relapse/progress
Watch and wait
Rituximab
monotherapy
In selected cases,
palliative radiation
(e.g. 2 × 2 Gy)
Chemoimmunotherapy
(e.g. BR, R-CHOP, R-CVP)
In selected cases, rituximab
monotherapy
Dependent on first-line regimen and
remission duration
• Chemoimmunotherapy (e.g. BR, R-
CHOP, R-CVP)
• Discuss high-dose consolidation
with ASCT
• Rituximab maintenance (every 3
months, up to 2 years)
• Alternatively, radioimmunotherapy
• In selected cases, discuss allogeneic
transplantation
Dependent on first-line regimen and
remission duration
• Chemoimmunotherapy (e.g. BR, R-
CHOP, R-CVP)
• Rituximab maintenance (every 3
months, up to 2 years)
• Alternatively, radioimmunotherapy
R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone; R-CVP, cyclophosphamide, vincristine and prednisolone; BR,
bendamustine–rituximab; CR, complete response; PR, partial response; ASCT, autologous stem-cell transplantation.
aAccording to biological age
Table 8. Summary of recommendations
In localised stages: discuss radiation (24–36 Gy)
In advanced stages: treatment depends on clinical risk factors,
symptoms and patient perspective
Standard approach in asymptomatic advanced cases: watch and wait
In advanced symptomatic cases
Combined chemoimmunotherapy for long-term remissions
Rituximab maintenance for consolidation
Relapse is frequently sensitive to conventional approaches
Autologous (and allogeneic) transplantation should be only
discussed in relapse
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• Minimal adequate radiological or ultrasound examinations
every 6 months for 2 years and annually thereafter. Regular
CT scans are not mandatory outside clinical trials, especially
if abdominal ultrasound is applicable. PET-CT should not be
used for surveillance.
• MRD screening may be carried out in clinical studies but
should not guide therapeutic strategies.
note
A summary of recommended treatment strategies outside clinic-
al studies is provided in Table 7, and a summary of recommen-
dations is provided in Table 8. Levels of evidence and grades of
recommendation have been applied using the system shown in
Table 9. Statements without grading were considered justified
standard clinical practice by the experts and the ESMO faculty.
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